Clinical Trial Update: Study of Everolimus in the Treatment of Advanced Malignancies in Patients With Peutz-Jeghers Syndrome [Phase 2]

View source ↗

Summary

The Phase 2 trial of Everolimus for advanced malignancies in Peutz-Jeghers syndrome has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neoplasm
• Neoplasms
• Peutz-jeghers Syndrome

Drugs mentioned

• Afinitor (everolimus)

Snippet

Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Conditions: Peutz-Jeghers Syndrome, Neoplastic Processes | Phase 2 | Status: WITHDRAWN